China Establishes Fast-Track Approval Process For New Flu Anti-Virals
This article was originally published in PharmAsia News
Chinese authorities have made plans to fast-track the nation's drug-approval process, but only for products aimed at treating an epidemic, beginning with the A(H1N1) swine flu. China's State FDA established a team of review experts to be ready to speed the process for those drugs without sacrificing quality issues. A spokeswoman said the new procedures are to be used for new drugs only when the public health is threatened. (Click here for more
You may also be interested in...
This month’s column covers deals announced between 1-23 April 2020.
Celltrion’s Truxima has become the first rituximab biosimilar, and just the second biosimilar overall, to be prequalified by the WHO.
EU MDR Panel Discussion: Why An Extra Year Is Not Really A Delay For The MDR – How To Survive Changing And Confusing Times
26 May 2020, the date that the Medical Device Regulation was originally due to apply in the EU, was a good time to take stock of where the medtech sector finds itself. Three of the most renowned and outspoken experts on the EU medical device regulatory system gave their views in this exclusive interview.